| Back to Back Issues Page |
| Issue #28-- Stay Healthy With These Immune Boosting Foods December 12, 2005 |
The World's Most Practical Healthy Eating E-zine |
| Back to Back Issues Page |
Wednesday, November 5, 2008
Issue #28-- Stay Healthy With These Immune Boosting Foods
Scientists turbo-charge immune cells to fight cancer - Yahoo! Canada News
0
* What's this
PARIS (AFP) - Scientists in the United States have created super-charged immune cells that helped beat back cancer tumours in half of a small group of patients tested, according to a study released Sunday.
ADVERTISEMENT
Adding an artificial receptor to T-lymphocytes immune cells boosted their ability to fight a deadly form of cancer called neuroblastoma, the researchers reported.
Neuroblastoma attacks the nervous system. While fairly rare, it accounts for seven percent of all childhood cancers, and 15 percent of non-adult cancer deaths.
In two-thirds of cases, it is not diagnosed until it has already spread to other parts of the body.
In their natural state, T-lymphocytes do not survive very long and lack the molecules that would target cancer cells in tumours.
To overcome this double deficiency, a team of researchers led by Malcolm Brenner at the Baylor College of Medicine in Houston, Texas first selected immune cells naturally stimulated by a common but harmless virus called Epstein-Barr.
They then modified these cells to express a receptor keyed to specific proteins found in human neuroblastoma cells.
'In effect, the T-lymphocytes trampoline off the virus and onto the tumor,' said Brenner."
Saturday, November 1, 2008
Bilateral orchiectomy with or without flutamide fo...[N Engl J Med. 1998] - PubMed Result
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Johns Hopkins Hospital, Baltimore, MD, USA.
BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.
PMID: 9761805 [PubMed - indexed for MEDLINE]
